clinical trial · NCT07614477
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
Everest Medicines (China) Co.,Ltd.·phase2·recruiting·n = 45
Minimal Change Disease (MCD)IgA Nephropathy (IgAN)Focal Segmental Glomerulosclerosis (FSGS)EVER001
brief summary
This is a Phase 1b/2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN. EVER001 acts on multiple immune pathways without directly affecting T cells or depleting B cells (both are lymphocytes). The study will be conducted at \~30 centers in China, enrolling 45 participants aged 18-75 years (15 per indication). The IMP is a 100 mg oral capsule, dosed at 200 mg twice daily (2 capsules per dose, 4 daily) for 52 weeks.
started
May 15, 2026
primary completion
Dec 31, 2028
completion
Mar 31, 2029
last updated
May 29, 2026
official title
The Sub-Study 3 of A Phase 1b/2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases (ES108001)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol